INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 418m ago
HOUSE PTR17m ago
SEC 13F17m ago
ROBINHOOD CHAIN17m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Guarini Kathryn reported REGN

Director · REGENERON PHARMACEUTICALS, INC. · REGENERON PHARMACEUTICALS, INC. — Non-Qualified Stock Option (right to buy)

Side
M
Value
—
Shares
400
Price
—
Executed
Oct 30, 2026
Disclosed
Nov 3, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Oct 30 executedNov 3, 2026 disclosed

REGN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
7/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 111.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · REGN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    12
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Gift
    		G—
    15 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    6,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    FR
    Fenimore Christopher R.EVP Finance CFO
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.29M
    6,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    34
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$194K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$2.58M
    2,670 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    7,830 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$4.69M
    12.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    40
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.18M
    1,224 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    12.3K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Tax withholding
    		F$8.26M
    8,686 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.47M
    1,522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    37
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$519K
    540 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    48
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$6.83M
    7,073 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$4.18M
    4,338 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    40
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$1.01M
    1,040 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M—
    7,439 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    37
    LJ
    Larosa Joseph JEVP General Counsel and Secret
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$509K
    527 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    22
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.83M
    7,439 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    26
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Option exercise
    		M$2.95M
    7,830 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    44
    SL
    Sing George LDirector
    REGNREGENERON PHARMACEUTICALS, INC.
    Open-market sale
    		SELL$2.43M
    2,522 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001992352-26-000009
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 30, 2026
    Published
    Nov 3, 2026
    Ingested by INSIDER
    Nov 5, 02:08 UTC
    Last re-read
    Nov 5, 02:08 UTC

    Extracted facts

    Filer
    Guarini Kathryn
    Role
    Director
    Transaction
    Option exerciseAs filed: “M”
    Asset
    REGENERON PHARMACEUTICALS, INC. — Non-Qualified Stock Option (right to buy)
    Ticker
    REGN
    Shares
    400
    Price per share
    $0
    Execution date (reported)
    Oct 30, 2026
    Owned after transaction
    758 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    What this establishes

    Guarini Kathryn filed this Form 4 reporting a option exercise of REGN on Oct 30, 2026. It became public on Nov 3, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Guarini Kathryncik:0001992352
    Issuer
    REGENERON PHARMACEUTICALS, INC.cik:0000872589

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.